| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8349619 | Pharmacological Reports | 2018 | 29 Pages |
Abstract
CYP2C19 genotype only partially determines the CYP2C19 phenotypic appearance; co-medication, diseases with inflammatory processes and aspecific factors, such as chronic alcohol consumption and amoxicillin-clavulanic acid therapy (or any drug therapy resulting in liver injury) seem to be potential phenotype-modifying factors.
Keywords
Personalized medicationPXRGAPDHCyPCytochrome P450confidence intervalCARintermediate metabolizerextensive metabolizerpoor metabolizerpolymerase chain reactionPCRGenetic polymorphismSingle nucleotide polymorphismSNPglyceraldehyde 3-phosphate dehydrogenaseconstitutive androstane receptorPregnane X receptorglucocorticoid receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Ádám Ferenc Kiss, Dorottya Vaskó, Máté Tamás Déri, Katalin Tóth, Katalin Monostory,